Physician
Hematology and Oncology Associates of Northeastern PA, PC
Hematology and Oncology Associates of Northeastern PA, PC was paid $1.06M by Medicaid between Jan 2018 and Dec 2024, across 26 billing codes. Its largest line is J9271, Injection, pembrolizumab, 1 mg — 32% of everything it billed.
33Billing provider infoHEMATOLOGY AND ONCOLOGY ASSOCIATES OF NORTHEASTERN PA, PC
DUNMORE, PA 18512
DUNMORE, PA 18512
33aNPI1164538724assigned 08/23/2006
33bProvider typeHematology & Oncology Physician
28Total paid$1.06M
24GClaims49,645
24DCodes billed26
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Hematology & Oncology Physician providers in Pennsylvania
Rank by total paid#2 of 81
Median peer was paid$3K
This provider vs. median334×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 265 | $997.03 | |
| 2019 | 440 | $3K | |
| 2020 | 1,291 | $22K | |
| 2021 | 12,480 | $557K | |
| 2022 | 12,143 | $168K | |
| 2023 | 12,373 | $173K | |
| 2024incomplete | 10,653 | $141K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 32% | 103 | 77 | $346K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 20% | 5,576 | 5,150 | $214K |
| 80053 | Comprehensive metabolic panel | 9.9% | 11,134 | 9,391 | $106K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | 9.4% | 1,726 | 1,302 | $100K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 6.6% | 847 | 569 | $71K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 5.4% | 11,956 | 10,065 | $58K |
| J1750 | Injection, iron dextran, 50 mg | 3.6% | 500 | 494 | $38K |
| 82728 | 3.2% | 3,364 | 3,258 | $34K | |
| 83540 | 2.3% | 3,444 | 3,329 | $25K | |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.3% | 947 | 932 | $24K |
| 83550 | 1.4% | 3,432 | 3,318 | $15K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 271 | 202 | $10K |
14 more codes
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 481 | $8K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 427 | $6K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 905 | $4K |
| 86300 | <1% | 181 | $3K | |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 450 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,488 | $443.72 |
| 96367 | <1% | 24 | $379.72 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,143 | $206.80 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 369 | $149.27 |
| 85046 | <1% | 13 | $78.81 | |
| 36415 | Collection of venous blood by venipuncture | 0% | 107 | $0.00 |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | 0% | 74 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 668 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLEANDRI, MICHELLE (CEO)